Onconetix Completes Reverse Stock Split to Maintain Listing

Onconetix ( (ONCO) ) has issued an update.

Onconetix, Inc., a commercial-stage biotechnology firm specializing in men’s health and oncology diagnostics, including its EU-approved Proclarix prostate cancer test, continues to trade on the Nasdaq Capital Market under the symbol ONCO. The company aims to grow its presence in prostate cancer testing, with plans to introduce Proclarix as a lab-developed test in the U.S. through a collaboration with Labcorp.

On February 3, 2026, Onconetix shareholders approved a reverse stock split authorization, and on March 6, 2026, the board set the split ratio at 1-for-5. The reverse stock split took effect at 12:01 a.m. Eastern Time on March 25, 2026, reducing the number of outstanding common shares from roughly 3.6 million to about 0.7 million while leaving authorized share count and par value unchanged.

Following the effective date, Onconetix’s common stock began trading on a split-adjusted basis on Nasdaq under a new CUSIP, 68237Q 302, with all stockholders treated uniformly aside from cash in lieu of fractional shares. The company stated that the move is intended to help maintain compliance with Nasdaq’s $1.00 minimum bid price requirement, potentially supporting its continued listing and providing greater stability and marketability of its shares for investors.

Spark’s Take on ONCO Stock

According to Spark, TipRanks’ AI Analyst, ONCO is a Underperform.

Onconetix’s overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score.

To see Spark’s full report on ONCO stock, click here.

More about Onconetix

Onconetix, Inc. is a commercial-stage biotechnology company focused on developing and commercializing innovative solutions for men’s health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union, and it plans to market the test in the U.S. as a lab-developed test through a license agreement with Labcorp.

Operating under the Nasdaq ticker ONCO, Onconetix targets the prostate cancer diagnostics market as part of its broader oncology and men’s health portfolio. The company’s strategy centers on leveraging its proprietary diagnostic assets and partnerships to expand its commercial footprint in key global healthcare markets.

Average Trading Volume: 78,253

Technical Sentiment Signal: Sell

Current Market Cap: $2.31M

See more insights into ONCO stock on TipRanks’ Stock Analysis page.